Graham tells FDA to pull 'toxic' Ketek from market

Share this article:
FDA drug safety expert, whistleblower Dr. David Graham, has called on FDA officials to pull from the market Sanofi-Aventis' controversial antibiotic Ketek, saying it is as toxic, "if not more so," as three other drugs [Rezulin, Trovan and Duract] pulled from the market for liver problems. The FDA has already revised Ketek's labeling.
Share this article:
close

Next Article in News

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.